Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan and Busulfan Followed by PBSCT for Multiple Myeloma
NCT00313625Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2005
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan and busulfan in multiple myeloma (MM), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Transplant-related mortality at 180 days. Started Sep 2005; status: completed.
02
Drugs
melphalanbusulfan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00313625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00313625.